A molecular glue to overcome cancer drug resistance?

A molecular glue to overcome cancer drug resistance?

Publication date: Jun 06, 2019

This led the Nobel Prize committee in 2018, to award Dr. James P. Allison the Nobel Prize. .. To treat melanoma, the most serious type of skin cancer, doctors have turned to surgery, chemotherapy, radiation therapy, and even immunotherapy, among other treatment options. 11, Pages 751: PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma Piperno-Neumann Roman-Roman NcE9mati Uveal melanoma (UM) remains without effective therapy at the metastatic stage, which is associated with BAP-1 (BRCA1 associated protein) mutations. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. The recent introduction of immune checkpoint inhibitors (ICI), has resulted in an increase in overall survival (OS) rates of patients with advanced NSCLC, as well as melanoma, urothelial carcinoma, renal cell carcinoma and head and neck carcinoma. 11, Pages 714: Targeting the Interplay between and the Immune System for Effective Immunotherapy Emily Roarty Jing Wang Fei Yang Michelle Barton Jeffrey Rosen Sendurai Mani Over the last decade, both early diagnosis and targeted therapy have improved the survival rates of many cancer patients. Most recently, immunotherapy has revolutionized the treatment options for cancers such as melanoma. Molecular characterization of non-responsive cancers suggest that an embryonic program known as epithelial-mesenchymal transition (EMT), which is .. . Evaluation of 18FFDG uptake after anti PD-1 therapy in mice Conclusion: This study is the first to assess early changes in [18F]FDG uptake by anti PD-1 treatment in a mouse B16F10 melanoma model.

Concepts Keywords
Acute Myeloid Leukemia Lung breast cancers
Adjuvant NSCLC
ARMM Non responsive cancers
BRCA1 Protein Lung cancer
Breast Melanoma skin cancer
Cancer Treatment B16F10 melanoma
Carcinoma Acute Myeloid Leukemia
Chemotherapies Radiation therapy
Chemotherapy Combination chemotherapy
Chimeric Antigen Receptor Surgery
Cisplatin Immunotherapy
Drug Resistance Chemotherapies
Duke University Medicine
EMT Clinical medicine
Epithelial Mesenchymal Transition Cancer
Glucose Cancer treatments
ICI Antineoplastic drugs
Immune System RTT
Immunotherapy Immune system
Interplay Oncology
Logistic Regression Targeted therapy
Lung PARP inhibitor
Lung Cancer Melanoma
Macrophages Checkpoint inhibitor
Malignancies Radiation
Mani Chemotherapy
Melanoma
Meta Analysis
Metabolism
Metastatic
Nobel Prize
Onslaught
PARP
Radiation Therapy
Renal Carcinoma
Skin Cancer
Small Molecule
T Cells
Targeted Therapy
Th1
Th2
Tregs
Tumor
Urothelial Carcinoma
Uveal Melanoma
Vivo
Xenografts

Semantics

Type Source Name
disease MESH cancer
disease DOID cancer
gene UNIPROT SMIM10L2B
gene UNIPROT SMIM10L2A
gene UNIPROT MAP6
disease MESH melanoma
disease DOID melanoma
pathway BSID Melanoma
disease MESH DNA damage
drug DRUGBANK Cisplatin
disease DOID Acute Myeloid Leukemia
pathway BSID Acute myeloid leukemia
gene UNIPROT RPL17
gene UNIPROT PDCD1
gene UNIPROT CTLA4
pathway BSID Immune System
drug DRUGBANK Tropicamide
gene UNIPROT NELFCD
disease MESH development
gene UNIPROT SPG7
gene UNIPROT PRKAR1A
gene UNIPROT NR1I3
gene UNIPROT CASR
gene UNIPROT CXADR
gene UNIPROT TRIM13
gene UNIPROT MTUS2
gene UNIPROT MTUS1
disease MESH skin cancer
disease DOID skin cancer
disease DOID cutaneous melanoma
disease DOID mucosal melanoma
gene UNIPROT COL11A2
gene UNIPROT PARP1
disease MESH Uveal Melanoma
disease DOID Uveal Melanoma
gene UNIPROT RNF2
gene UNIPROT MAGI1
gene UNIPROT BRCA1
pathway BSID DNA Repair
drug DRUGBANK Olaparib
drug DRUGBANK Pralatrexate
disease MESH non-small cell lung cancer
disease DOID non-small cell lung cancer
pathway BSID Non-small cell lung cancer
disease MESH Lung cancer
disease DOID Lung cancer
disease DOID head and neck carcinoma
gene UNIPROT FAM168B
disease MESH diagnosis
gene UNIPROT ITK
gene UNIPROT SLC22A3
gene UNIPROT SMUG1
pathway BSID Glucose metabolism

Similar

Leave a Comment

Your email address will not be published. Required fields are marked *